Central neurotoxicity of immunomodulatory drugs in multiple myeloma

Urmeel H. Patel, Muhammad A. Mir, Jeffrey K. Sivik, Divisha Raheja, Manoj K. Pandey, Giampaolo Talamo

Research output: Contribution to journalArticlepeer-review

10 Scopus citations

Abstract

Immunomodulatory drugs (IMiDs) currently used in the treatment of multiple myeloma, are thalidomide, lenalidomide and pomalidomide. One of the most common side effects of thalidomide is neurotoxicity, predominantly in the form of peripheral neuropathy. We report 6 cases of significant central neurotoxicity associated with IMiD therapy. Treatment with thalidomide (1 patient), lenalidomide (4 patients), and pomalidomide (1 patient) was associated with various clinical manifestations of central neurotoxicity, including reversible coma, amnesia, expressive aphasia, and dysarthria. Central neurotoxicity should be recognized as an important side effect of IMiD therapy.

Original languageEnglish (US)
Pages (from-to)12-14
Number of pages3
JournalHematology Reports
Volume7
Issue number1
DOIs
StatePublished - Mar 3 2015

All Science Journal Classification (ASJC) codes

  • Hematology

Fingerprint Dive into the research topics of 'Central neurotoxicity of immunomodulatory drugs in multiple myeloma'. Together they form a unique fingerprint.

Cite this